Loading...

Madrigal Pharmaceuticals

Nasdaq:MDGL
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MDGL
Nasdaq
$2B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • Madrigal Pharmaceuticals has significant price volatility in the past 3 months.
MDGL Share Price and Events
7 Day Returns
-4.2%
NasdaqCM:MDGL
1%
US Biotechs
0.2%
US Market
1 Year Returns
-14%
NasdaqCM:MDGL
-4.6%
US Biotechs
2.9%
US Market
MDGL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Madrigal Pharmaceuticals (MDGL) -4.2% -7% -22% -14% - -
US Biotechs 1% -0% -3.2% -4.6% 3.8% 9.7%
US Market 0.2% -1.6% 2.4% 2.9% 36.1% 41%
1 Year Return vs Industry and Market
  • MDGL underperformed the Biotechs industry which returned -4.6% over the past year.
  • MDGL underperformed the Market in United States of America which returned 2.9% over the past year.
Price Volatility
MDGL
Industry
5yr Volatility vs Market
Related Companies

MDGL Value

 Is Madrigal Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Madrigal Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $98.8.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Madrigal Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Madrigal Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:MDGL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-2.75
NasdaqCM:MDGL Share Price ** NasdaqCM (2019-05-23) in USD $98.8
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,085 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Madrigal Pharmaceuticals.

NasdaqCM:MDGL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:MDGL Share Price ÷ EPS (both in USD)

= 98.8 ÷ -2.75

-35.94x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Madrigal Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.
  • Madrigal Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Madrigal Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqCM:MDGL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -35.94x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
9.8%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.26x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Madrigal Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Madrigal Pharmaceuticals's assets?
Raw Data
NasdaqCM:MDGL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $30.39
NasdaqCM:MDGL Share Price * NasdaqCM (2019-05-23) in USD $98.8
United States of America Biotechs Industry PB Ratio Median Figure of 414 Publicly-Listed Biotechs Companies 3.35x
United States of America Market PB Ratio Median Figure of 5,201 Publicly-Listed Companies 1.84x
NasdaqCM:MDGL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:MDGL Share Price ÷ Book Value per Share (both in USD)

= 98.8 ÷ 30.39

3.25x

* Primary Listing of Madrigal Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Madrigal Pharmaceuticals is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Madrigal Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Madrigal Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MDGL Future Performance

 How is Madrigal Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
9.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Madrigal Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Madrigal Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Madrigal Pharmaceuticals's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Madrigal Pharmaceuticals's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:MDGL Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:MDGL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 9.8%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:MDGL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:MDGL Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 275 -89 -11 6
2022-12-31 83 -137 -101 4
2021-12-31 3 -107 -112 8
2020-12-31 0 -68 -84 9
2019-12-31 0 -50 -68 9
NasdaqCM:MDGL Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 -23 -42
2018-12-31 -26 -33
2018-09-30 -25 -30
2018-06-30 -25 -30
2018-03-31 -27 -32
2017-12-31 -22 -31
2017-09-30 -22 -30
2017-06-30 -26 -36
2017-03-31 -21 -31
2016-12-31 -18 -26
2016-09-30 -13 -21
2016-06-30 -5 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Madrigal Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Madrigal Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:MDGL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from Madrigal Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:MDGL Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.33 26.27 -6.48 6.00
2022-12-31 -3.67 5.83 -8.42 6.00
2021-12-31 -6.29 -4.35 -7.57 6.00
2020-12-31 -5.65 -4.73 -8.99 7.00
2019-12-31 -4.55 -4.05 -5.40 6.00
NasdaqCM:MDGL Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -2.75
2018-12-31 -2.22
2018-09-30 -2.11
2018-06-30 -2.22
2018-03-31 -2.46
2017-12-31 -2.54
2017-09-30 -2.54
2017-06-30 -3.25
2017-03-31 -3.76
2016-12-31 -5.07
2016-09-30 -1.77
2016-06-30 -7.48

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Madrigal Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Madrigal Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Madrigal Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MDGL Past Performance

  How has Madrigal Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Madrigal Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Madrigal Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Madrigal Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Madrigal Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Madrigal Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Madrigal Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:MDGL Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -41.53 19.17 32.56
2018-12-31 -32.81 15.29 25.39
2018-09-30 -29.78 12.11 23.03
2018-06-30 -29.63 8.94 23.50
2018-03-31 -31.52 7.85 25.21
2017-12-31 -31.15 7.67 24.39
2017-09-30 -30.46 6.91 23.40
2017-06-30 -36.14 9.14 24.53
2017-03-31 -30.67 8.06 19.80
2016-12-31 -26.39 6.59 15.93
2016-09-30 -20.52 5.10 11.18
2016-06-30 -8.27 1.12 4.06
2016-03-31 -7.18 0.83 2.60
2015-12-31 -6.84 0.81 2.43
2014-12-31 -4.49 0.55 0.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Madrigal Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Madrigal Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Madrigal Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Madrigal Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Madrigal Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MDGL Health

 How is Madrigal Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Madrigal Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Madrigal Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Madrigal Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Madrigal Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 531.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Madrigal Pharmaceuticals Company Filings, last reported 1 month ago.

NasdaqCM:MDGL Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 468.51 0.90 477.83
2018-12-31 476.98 0.00 483.72
2018-09-30 482.91 0.00 488.54
2018-06-30 486.09 0.00 490.31
2018-03-31 177.18 0.00 182.83
2017-12-31 182.26 0.00 191.53
2017-09-30 54.31 0.00 62.14
2017-06-30 61.63 0.00 67.17
2017-03-31 34.45 0.00 40.13
2016-12-31 36.41 0.00 40.50
2016-09-30 37.59 0.00 39.56
2016-06-30 -42.28 45.97 4.10
2016-03-31 -50.63 50.82 0.62
2015-12-31 -48.91 49.10 0.31
2014-12-31 -42.07 42.19 0.15
  • Madrigal Pharmaceuticals's level of debt (0.2%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Madrigal Pharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Madrigal Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • Madrigal Pharmaceuticals has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 33.7% each year.
X
Financial health checks
We assess Madrigal Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Madrigal Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MDGL Dividends

 What is Madrigal Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Madrigal Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought $2,000 of Madrigal Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Madrigal Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Madrigal Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:MDGL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2005 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:MDGL Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 3.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Madrigal Pharmaceuticals has not reported any payouts.
  • Unable to verify if Madrigal Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Madrigal Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Madrigal Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Madrigal Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Madrigal Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Madrigal Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Madrigal Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MDGL Management

 What is the CEO of Madrigal Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paul Friedman
COMPENSATION $5,628,666
AGE 75
TENURE AS CEO 2.8 years
CEO Bio

Dr. Paul A. Friedman, M.D., has been Chairman and Chief Executive Officer of Madrigal Pharmaceuticals, Inc. since July 22, 2016 and served as its President since July 22, 2016. Dr. Friedman is Co-Owner of SQN, LLC. He serves as a Partner of Vilicus Ventures, LLC. Dr. Friedman is a Cardiologist and Professor at Mayo Clinic. He is a Professor of Medicine and a consultant of cardiovascular electrophysiology. He has more than 20 years of experience in the pharmaceutical industry. He served as an Executive Chairman of Cerulean Pharma Inc. since October 29, 2014 until June 2016. He served as the Chief Executive Officer of Incyte Corporation from November 2001 to January 13, 2014 and served as its President from May 2004 to January 13, 2014. where he led a transformation of the business from genomics to a therapeutic focus establishing its foundation as a leader in oncology. From 1998 to October 2001, Dr. Friedman served as the President of DuPont Pharmaceuticals Research Laboratories. From 1994 to 1998, he served as the President of Research and Development of The DuPont Merck Pharmaceutical Company. From 1991 to 1994, he served as Senior Vice President at Merck Sharp & Dohme Research Laboratories. He held executive and R&D positions at Merck Research Laboratories. From 1985 to 1991, he held several executive positions at Merck. From 1974 to 1985, he served as an Associate Professor of Medicine and Pharmacology at Harvard Medical School. He has been Director at Alexion Pharmaceuticals, Inc. since September 14, 2017. He has been a Director of Cerulean Pharma Inc. since January 2014 until 2017 and Durata Therapeutics, Inc. since May 16, 2013 until 2014. He has been a Non Executive Director of Gliknik, Inc. since February 25, 2013. He has been an Independent Director of Navitor Pharmaceuticals, Inc. since June 2015. He has been a Director of Incyte Corporation since November 2001. He has been Member of Advisory Board at HeraMED Limited since May 2019. He has been a Member of Clinical and Scientific Advisory Board of Verastem, Inc. since May 2017 and served as its Independent Director since May 2014 until April 27, 2017. Dr. Friedman served as a Director of Synta Pharmaceuticals Corp. since March 2014 until 2016. He served as a Director of Auxilium Pharmaceuticals Inc. from June 2010 to January 29, 2015. He served as a Director of Sirtris Pharmaceuticals, Inc. from March 2008 to June 2008. He served as a Director of Bausch & Lomb Incorporated from June 2004 to October 2007. He is a Diplomate of the American Board of Internal Medicine and a Member of the American Society of Clinical Investigation. He is the author of over 100 scientific publications. He has over 40 biomedical patents and has authored over 300 scientific publications, including books, book chapters and original articles. He is the reviewer or editor of over 15 influential medical journals and directs national and international medical education meetings. He has been the principal investigator of large, international, multicenter trials. He has also been the recipient of federal and regional research awards to assess and develop new healthcare technologies. He is the Vice Chair of Academic Affairs and Faculty Development at the Mayo Clinic. He is the Vice Chair of the Division of Cardiovascular Medicine at the Mayo Clinic. Dr. Friedman received an M.D. Degree from Harvard Medical School in 1969 and B.S. degree in Biology from Princeton University, Princeton, New Jersey, in 1964.

CEO Compensation
  • Paul's compensation has increased whilst company is loss making.
  • Paul's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Madrigal Pharmaceuticals management team in years:

2.8
Average Tenure
65
Average Age
  • The tenure for the Madrigal Pharmaceuticals management team is about average.
Management Team

Paul Friedman

TITLE
Chairman & CEO
COMPENSATION
$6M
AGE
75
TENURE
2.8 yrs

Becky Taub

TITLE
Founder
COMPENSATION
$4M
AGE
66

Marc Schneebaum

TITLE
Senior VP & CFO
COMPENSATION
$3M
AGE
64
TENURE
2.8 yrs

Brian Lynch

TITLE
Senior VP & General Counsel
AGE
57
TENURE
0.3 yrs

Tom Hare

TITLE
Senior Vice President of Clinical Management
Board of Directors Tenure

Average tenure and age of the Madrigal Pharmaceuticals board of directors in years:

2.8
Average Tenure
72
Average Age
  • The average tenure for the Madrigal Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Paul Friedman

TITLE
Chairman & CEO
COMPENSATION
$6M
AGE
75
TENURE
2.8 yrs

Becky Taub

TITLE
Founder
COMPENSATION
$4M
AGE
66
TENURE
7.7 yrs

Ken Bate

TITLE
Director
COMPENSATION
$2M
AGE
68
TENURE
2.8 yrs

Keith Gollust

TITLE
Director
COMPENSATION
$2M
AGE
72
TENURE
2.8 yrs

Rich Levy

TITLE
Director
COMPENSATION
$2M
AGE
60
TENURE
2.8 yrs

Fred Craves

TITLE
Lead Director
COMPENSATION
$2M
AGE
72
TENURE
2.8 yrs

Dave Milligan

TITLE
Director
COMPENSATION
$2M
AGE
77
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
24. Nov 18 Buy Paul Friedman Individual 20. Nov 18 20. Nov 18 4,000 $117.88 $471,520
19. Nov 18 Buy Paul Friedman Individual 19. Nov 18 19. Nov 18 4,000 $124.00 $496,000
19. Nov 18 Buy Frederick Craves Individual 19. Nov 18 19. Nov 18 2,000 $125.00 $249,387
13. Jun 18 Sell Marc Schneebaum Individual 11. Jun 18 11. Jun 18 -2,142 $287.46 $-615,739
13. Jun 18 Sell Bay City Capital LLC Company 11. Jun 18 11. Jun 18 -280,000 $287.46 $-80,488,800
13. Jun 18 Sell SQN, LLC Company 11. Jun 18 11. Jun 18 -73,526 $287.46 $-21,135,784
X
Management checks
We assess Madrigal Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Madrigal Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MDGL News

Simply Wall St News

How Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Can Impact Your Portfolio Volatility

Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … If this beta value holds true in the future, Madrigal Pharmaceuticals shares are likely to rise more than the market when the market is going up, but fall faster when the market is going down.

Simply Wall St -

Has Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Got Enough Cash?

Mid-caps stocks, like Madrigal Pharmaceuticals, Inc. … While they are less talked about as an investment category, mid-cap risk-adjusted returns have generally been better than more commonly focused stocks that fall into the small- or large-cap categories. … MDGL’s financial liquidity and debt position will be analysed in this article, to get an idea of whether the company can fund opportunities for strategic growth and maintain strength through economic downturns.

Simply Wall St -

Need To Know: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Insiders Have Been Buying Shares

So shareholders might well want to know whether insiders have been buying or selling shares in Madrigal Pharmaceuticals, Inc. … The Last 12 Months Of Insider Transactions At Madrigal Pharmaceuticals. … Although we don't gain confidence from insider selling, we note that this large sale was at well above current price of US$118

Simply Wall St -

What You Must Know About Madrigal Pharmaceuticals Inc's (NASDAQ:MDGL) Financial Health

Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), with a market cap of US$3.1b, often get neglected by retail investors. … Don’t forget that this is a general and concentrated examination of Madrigal Pharmaceuticals's financial health, so you should conduct further analysis. … View our latest analysis for Madrigal Pharmaceuticals

Simply Wall St -

Has Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Got Enough Cash?

Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), with a market cap of US$4.51b, often get neglected by retail investors. … While they are less talked about as an investment category, mid-cap risk-adjusted returns have generally been better than more commonly focused stocks that fall into the small- or large-cap categories. … Check out our latest analysis for Madrigal Pharmaceuticals

Simply Wall St -

Who Are The Top Investors In Madrigal Pharmaceuticals Inc (MDGL)?

I am going to take a deep dive into Madrigal Pharmaceuticals Inc’s (NASDAQ:MDGL) most recent ownership structure, not a frequent subject of discussion among individual investors. … Private Company Ownership Potential investors in MDGL should also look at another important group of investors: private companies, with a stake of 5.83%, who are primarily invested because of strategic and capital gain interests. … Thus, investors should dig deeper into MDGL's business relations with these companies and how it can affect shareholder returns in the long-term.What this means for you: The company's high institutional ownership makes margin of safety a very important consideration to existing investors since long bull and bear trends often emerge when these big-ticket investors see a change in long-term potential of the company.

Simply Wall St -

Is Madrigal Pharmaceuticals Inc (MDGL) On The Right Side Of Disruption?

NasdaqCM:MDGL PE PEG Gauge Nov 23rd 17 The biotech industry is trading at a PE ratio of 27x, higher than the rest of the US stock market PE of 22x. … If your initial investment thesis is around the growth prospects of MDGL, there are other biotech companies that have delivered higher growth, and perhaps trading at a discount to the industry average. … Although its growth has delivered lower growth relative to its biotech peers in the near term, the market may be pessimistic on the stock, leading to a potential undervaluation.

Simply Wall St -

MDGL Company Info

Description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company’s lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.

Details
Name: Madrigal Pharmaceuticals, Inc.
MDGL
Exchange: NasdaqCM
Founded: 2011
$1,523,334,363
15,418,364
Website: http://www.madrigalpharma.com
Address: Madrigal Pharmaceuticals, Inc.
Four Tower Bridge,
Suite 400,
West Conshohocken,
Pennsylvania, 19428,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM MDGL New Common Stock Nasdaq Capital Market US USD 25. Jul 2016
DB YDO1 New Common Stock Deutsche Boerse AG DE EUR 25. Jul 2016
LSE 0JXI New Common Stock London Stock Exchange GB USD 25. Jul 2016
Number of employees
Current staff
Staff numbers
17
Madrigal Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/24 00:46
End of day share price update: 2019/05/23 00:00
Last estimates confirmation: 2019/05/15
Last earnings filing: 2019/05/08
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.